Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057172 · ClinicalTrials.gov registry record · Phase 2
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
A Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 254
- Enrollment target
NCT02057172: Completed Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
NCT02057172 is a Phase 2 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 254 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02057172, a Phase 2 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 254 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG liraglutide
- DRUG HM11260C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT02057172 record still lists
NCT02057172 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02057172 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02057172 about?
NCT02057172 is a clinical study titled "Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes". The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT02057172?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2014-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02057172?
The interventions under investigation include: Placebo (DRUG), liraglutide (DRUG), HM11260C (DRUG).
Who is sponsoring clinical trial NCT02057172?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02057172's enrollment target sits among peer trials
254 219th of 2000 higher than 1,781 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia